Early onset recall pneumonitis during targeted therapy with sunitinib

BMC Cancer

Case Report

Sohei Harada¹  Takuyo Kozuka²  Kazunari Miyazawa²  Keita Kudo³  Gen Sukegawa⁴  Shinya Yamamoto⁴  Junji Yonese⁴  Shinichi Kitsukawa⁴  Takeshi Yuasa⁴ 

[1] Department of Infectious Diseases, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 135-8550, Ariake, Tokyo, Japan;Department of Radiation Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 135-8550, Ariake, Tokyo, Japan;Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 135-8550, Ariake, Tokyo, Japan;Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 135-8550, Ariake, Tokyo, Japan;

关键词: Sunitinib;    Renal cell cancer;    Recall pneumonitis;    Radiation;    Radiation pneumonitis;   

DOI  :  10.1186/1471-2407-13-3

 received in 2012-09-25, accepted in 2012-12-27,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundSunitinib interacts with radiation therapy, leading to synergism of the toxicities of these treatments. Radiation recall pneumonitis is a rare but serious complication of targeted therapy with tyrosine kinase inhibitors.Case presentationThe case of a patient with metastatic renal cell cancer (RCC) who developed recall pneumonitis on the first cycle of systemic sunitinib treatment is reported here. A 65-year-old man with RCC and bone metastasis underwent radiation therapy on his thoracic vertebrae (Th5-8) with a total dose of 24 Gy. Sunitinib (37.5 mg) was started 14 days after completing the radiation therapy. On the 14th day of sunitinib treatment, the patient developed progressive fever with worsening of dyspnea and general weakness. Treatment with pulse administration of prednisolone 1,000 mg for 3 days was initiated. Thereafter, the symptoms and the radiological findings regarding the interstitial filtration gradually improved over 7 days.ConclusionTo our knowledge, this is the first report of early onset recall pneumonitis during sunitinib therapy. At present, how sunitinib interacts with radiation therapy remains unclear. The possibility that tyrosine kinase inhibitor therapy, including with sunitinib, after radiation therapy may lead to adverse effects should be kept in mind.

【 授权许可】

CC BY   
© Yuasa et al; licensee BioMed Central Ltd. 2013